Mirae Asset Global Investments Co. Ltd. trimmed its holdings in Danaher Co. (NYSE:DHR – Free Report) by 4.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 75,802 shares of the conglomerate’s stock after selling 3,420 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Danaher were worth $17,480,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the stock. Wedge Capital Management L L P NC raised its position in shares of Danaher by 3.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 38 shares during the last quarter. Meridian Financial Partners LLC raised its holdings in shares of Danaher by 4.4% during the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after acquiring an additional 40 shares during the last quarter. Kovack Advisors Inc. lifted its position in shares of Danaher by 3.4% in the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after acquiring an additional 41 shares in the last quarter. Well Done LLC boosted its stake in shares of Danaher by 1.2% in the third quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock worth $987,000 after acquiring an additional 42 shares during the last quarter. Finally, Waypoint Capital Advisors LLC increased its position in shares of Danaher by 0.9% during the third quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock worth $1,257,000 after purchasing an additional 42 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at Danaher
In related news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 10.90% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Analysis on Danaher
Danaher Stock Down 1.4 %
NYSE:DHR opened at $211.92 on Thursday. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $153.07 billion, a price-to-earnings ratio of 40.14, a price-to-earnings-growth ratio of 2.80 and a beta of 0.83. Danaher Co. has a 52 week low of $210.04 and a 52 week high of $281.70. The stock’s fifty day moving average is $234.50 and its two-hundred day moving average is $252.68.
Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the firm earned $2.09 EPS. Research analysts anticipate that Danaher Co. will post 7.77 EPS for the current year.
Danaher Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were paid a $0.27 dividend. The ex-dividend date was Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.51%. Danaher’s dividend payout ratio (DPR) is 20.45%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
- Five stocks we like better than Danaher
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Must-Have ETFs Set to Dominate This Quarter
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Seeking Stability? These 3 Stocks Offer Strong Potential
- What is Put Option Volume?
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.